LBP AM SA decreased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 6.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 344,424 shares of the company's stock after selling 24,363 shares during the quarter. LBP AM SA's holdings in Merck & Co., Inc. were worth $30,915,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quilter Plc increased its position in shares of Merck & Co., Inc. by 5.6% during the first quarter. Quilter Plc now owns 1,180,797 shares of the company's stock worth $105,988,000 after acquiring an additional 62,933 shares during the period. Simplicity Wealth LLC increased its position in shares of Merck & Co., Inc. by 991.7% during the first quarter. Simplicity Wealth LLC now owns 33,394 shares of the company's stock worth $2,997,000 after acquiring an additional 30,335 shares during the period. Napatree Capital LLC increased its position in shares of Merck & Co., Inc. by 13.0% during the fourth quarter. Napatree Capital LLC now owns 4,220 shares of the company's stock worth $420,000 after acquiring an additional 485 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Merck & Co., Inc. by 13.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 56,566 shares of the company's stock worth $5,118,000 after acquiring an additional 6,850 shares during the period. Finally, Summit Financial LLC increased its position in shares of Merck & Co., Inc. by 34.2% during the fourth quarter. Summit Financial LLC now owns 102,099 shares of the company's stock worth $10,229,000 after acquiring an additional 25,997 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on MRK. Cantor Fitzgerald lowered Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research report on Tuesday, May 20th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research note on Friday, April 25th. Citigroup reiterated a "neutral" rating and set a $84.00 target price (down previously from $115.00) on shares of Merck & Co., Inc. in a research note on Wednesday, May 14th. Finally, Guggenheim reiterated a "buy" rating and set a $115.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $109.19.
View Our Latest Stock Analysis on MRK
Insider Buying and Selling at Merck & Co., Inc.
In other news, SVP Dalton E. Smart III sold 4,262 shares of the stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the sale, the senior vice president owned 7,778 shares in the company, valued at approximately $643,707.28. This represents a 35.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.13% of the company's stock.
Merck & Co., Inc. Stock Performance
Shares of MRK traded up $2.37 during mid-day trading on Wednesday, hitting $83.74. 18,390,570 shares of the company's stock were exchanged, compared to its average volume of 13,340,532. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $129.93. The firm has a market capitalization of $210.27 billion, a P/E ratio of 12.19, a P/E/G ratio of 0.84 and a beta of 0.39. The business's 50 day moving average is $79.09 and its two-hundred day moving average is $86.73. The company has a current ratio of 1.41, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a net margin of 27.27% and a return on equity of 43.23%. The business had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same quarter in the prior year, the firm earned $2.07 earnings per share. The business's quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.
Merck & Co., Inc. Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th were paid a dividend of $0.81 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $3.24 annualized dividend and a dividend yield of 3.87%. Merck & Co., Inc.'s dividend payout ratio (DPR) is 47.16%.
About Merck & Co., Inc.
(
Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Featured Articles

Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report